DLBCL indicates diffuse large B-cell lymphoma; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; and R-ICE, rituximab, ifosfamide, carboplatin, etoposide.

*No randomization regarding PET response-adapted therapy.